Robigo

Robigo, Inc. is a privately held biotechnology company focused on developing next-generation engineered microbial biopesticides for sustainable crop protection. Headquartered in Cambridge, Massachusetts, and spun out of MIT around 2021, the firm engineers naturally occurring soil microbes using its proprietary ARGO platform. This technology combines synthetic biology, computational bioactive design, strain selection, and tools like CRISPR and RNA interference to program microbes that produce targeted active compounds, silencing essential genes in plant pathogens with precision while sparing beneficial organisms.

The company's primary activities center on combating soil-borne fungal diseases in major crops. Its lead product is an engineered microbial seed treatment for Sudden Death Syndrome in soybeans, which has matched the performance of commercial chemical fungicides in field trials at roughly half the cost, with a targeted U.S. commercial launch in 2028. A second program targets fusarium wilt, a leading disease in lettuce and berries, where trials demonstrated up to a threefold yield increase over untreated controls under high disease pressure, slated for 2029. Robigo emphasizes products that integrate seamlessly into existing grower practices, require no cold-chain storage, and deliver season-long protection from a single application.

Robigo operates mainly in the United States, with field trials across multiple states including the Midwest and West, and plans pipeline expansion into additional broadacre soil-borne pathogens in a market it estimates at $10 billion. As a venture-backed startup, it recently closed a Series A round led by Leaps by Bayer with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. In the agricultural biotechnology industry, Robigo positions itself as an innovator bridging the gap between traditional biologicals and synthetic chemistries by delivering chemical-level efficacy with improved safety, cost, and environmental profiles.